Skip to main content
. 2014 Sep 15;19(11):1169–1178. doi: 10.1634/theoncologist.2014-0190

Figure 2.

Figure 2.

Kaplan-Meier survival curves for the FOLFOX4 group versus the doxorubicin group (intention-to-treat cohort). (A): Overall survival at final analysis. (B): Overall survival at follow-up analysis. (C): Progression-free survival. +, Stratified log-rank test.

Abbreviations: CI, confidence interval; FOLFOX4, oxaliplatin, 5-fluorouracil, and leucovorin; HR, hazard ratio.